Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
12 studies found for:    mesothelioma AND South Carolina
Show Display Options
Rank Status Study
1 Completed Capecitabine in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
2 Recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelioid Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Drug: Pemetrexed Disodium;   Drug: Cisplatin;   Drug: Cediranib Maleate;   Other: Placebo
3 Completed S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: gemcitabine hydrochloride
4 Completed S0509: AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
5 Completed
Has Results
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib
6 Recruiting Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium;   Other: clinical observation
7 Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
8 Unknown  Collecting Tumor Samples From Patients With Gynecological Tumors
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
9 Completed PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
10 Active, not recruiting S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
11 Recruiting Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab;   Drug: Placebo
12 Recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011

Indicates status has not been verified in more than two years